# Cardiovascular endpoints and psychosocial challenges of lipoprotein(a) of 5726 participants in the ELITE-study over 5 years

**Authors:** Bastian Schrader, Friedrich Lorenz, Armin Weers, Matteo Scorcelletti, Stephan Lüders, Bernhard Vaske, Sandra Garstecki, Joachim Schrader, Albrecht Elsässer

PMC · DOI: 10.1186/s12944-025-02785-2 · Lipids in Health and Disease · 2025-11-14

## TL;DR

A study of 5726 people found that high Lp(a) levels increase cardiovascular risks and cause psychological stress, even after personalized prevention advice.

## Contribution

The study is the first to investigate the psychological stress caused by elevated Lp(a) and its cardiovascular outcomes in a large cohort.

## Key findings

- Participants with elevated Lp(a) had significantly more cardiovascular events despite similar risk factors.
- Personalized prevention advice improved cardiovascular risk factors in both groups.
- Elevated Lp(a) was associated with psychological concern or anxiety in about 40% of participants.

## Abstract

Lipoprotein(a) [Lp(a)] is a known independent risk factor for cardiovascular disease, yet awareness and management remain limited. The psychosocial implications of elevated Lp(a)-levels have been poorly characterized.

To compare cardiovascular outcomes and cardiovascular risk factor (CVRF) modification in individuals with normal vs. elevated Lp(a) levels, and to assess the impact of individualized prevention recommendations. For the first time, the individual psychological stress caused by Lp(a) is being surveyed.

The ELITE study is a prospective, interventional cohort study conducted in north-western Germany. Participants were regularly assessed for CVRFs, including Lp(a), hypertension, dyslipidemia, diabetes mellitus, weight, nicotine – as well as lipoprotein (a), physical activity, dietary habits, depression and stress. They received written, personalized prevention recommendations. Follow-up averaged 4.4 years. Two groups were analyzed: Group 1 (Gr1, n=3,241) with normal Lp(a), and Group 2 (Gr2, n=841) with elevated Lp(a ≥75 nmol/l).

Gr2 (mean Lp(a) 154.8 nmol/l) and Gr1 (mean Lp(a) 16.4 nmol/l) were comparable in age (~53 years) and sex distribution (~49% female). Most participants with elevated Lp(a) were previously unaware of their levels; 30% were referred to specialists, and ~40% reported concern or anxiety. Combined cardiovascular endpoints (CHD, stroke, heart failure, PAD, carotid stenosis, AF) occurred significantly more often in Gr2 (p<0.001), despite similar CVRF profiles, except for higher baseline LDL-C in Gr2 (p<0.001). Hypertension (61%) and physical inactivity (57%) were the most prevalent CVRFs. Personalized prevention measures led to significant improvements in blood pressure, LDL-C, smoking, physical activity, and weight in both groups. Lipid-lowering therapy improved markedly in Gr2 (12% to 23%).

Elevated Lp(a) is associated with a significantly higher rate of cardiovascular events, independent of traditional CVRFs. This confirms a causal role of Lp(a) in CV morbidity. Personalized written prevention recommendations improved CVRFs across both groups, though further optimization is needed. Notably, elevated Lp(a) also imposes a psychosocial burden, underlining the need for enhanced education, counseling, and clinical pathways.

## Linked entities

- **Diseases:** cardiovascular disease (MONDO:0004995), dyslipidemia (MONDO:0002525), diabetes mellitus (MONDO:0005015), heart failure (MONDO:0005252), stroke (MONDO:0005098), carotid stenosis (MONDO:0001612), atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Diseases:** Hypertension (MESH:D006973), anxiety (MESH:D001007), stroke (MESH:D020521), cardiovascular disease (MESH:D002318), dyslipidemia (MESH:D050171), diabetes mellitus (MESH:D003920), depression (MESH:D003866), heart failure (MESH:D006333), carotid stenosis (MESH:D016893)
- **Chemicals:** Lipid (MESH:D008055), nicotine (MESH:D009538), LDL-C (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12619217/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12619217/full.md

## References

8 references — full list in the complete paper: https://tomesphere.com/paper/PMC12619217/full.md

---
Source: https://tomesphere.com/paper/PMC12619217